MXPA02012067A - Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico. - Google Patents

Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.

Info

Publication number
MXPA02012067A
MXPA02012067A MXPA02012067A MXPA02012067A MXPA02012067A MX PA02012067 A MXPA02012067 A MX PA02012067A MX PA02012067 A MXPA02012067 A MX PA02012067A MX PA02012067 A MXPA02012067 A MX PA02012067A MX PA02012067 A MXPA02012067 A MX PA02012067A
Authority
MX
Mexico
Prior art keywords
subject
progenitor cells
endothelial progenitor
present
tissue
Prior art date
Application number
MXPA02012067A
Other languages
English (en)
Inventor
Silviu Itescu
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MXPA02012067A publication Critical patent/MXPA02012067A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invencion provee un metodo para estimular la vasculogenesis de tejido danado por infarto al miocardio en un sujeto que comprende: (a) remover celulas no diferenciadas de un sitio en el sujeto; (b) recuperar celulas precursoras endoteliales en las celulas no diferenciadas; (c) introducir las celulas precursoras endoteliales provenientes del paso (b) en un sitio diferente en el individuo de modo tal que los precursores migren hacia el tejido y estimulen la revascularizacion del mismo. Las celulas no diferenciadas se pueden remover directamente o mediante movilizacion. Las celulas precursoras endoteliales se pueden expandir antes de la introduccion en el sujeto. La presente invencion tambien provee un metodo para inducir la angiogenesis en un tejido de peri-infarto. La presente invencion tambien provee un metodo para incrementar en forma selectiva el trafico de precursores de celula endotelial derivados de medula osea de humano hacia el sitio de tejido danado por dano isquemico que comprende: (a) administrar a un sujeto celulas precursoras endoteliales; (b) administrar quimiocinas al sujeto para que atraigan los precursores de celula endotelial hacia el tejido isquemico. La presente invencion provee un metodo para estimular la vasculogenesis o angiogenesis de tejido danado por infarto al miocardio en un sujeto que comprende inyectar celulas no diferenciadas alogenicas en un sujeto. La presente invencion tambien provee un metodo para mejorar la funcion del miocardio en un sujeto que ha padecido un infarto al miocardio que comprende cualquiera de los presentes metodos. La presente invencion tambien provee un metodo para mejorar la funcion del miocardio en un sujeto que ha padecido un infarto al miocardio que comprende inyectar G-CSF o anticuerpo anti-CXCR4 en el sujeto con el fin de movilizar las celulas precursoras endoteliales.
MXPA02012067A 2000-06-05 2001-06-05 Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico. MXPA02012067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58744100A 2000-06-05 2000-06-05
PCT/US2001/018399 WO2001094420A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury

Publications (1)

Publication Number Publication Date
MXPA02012067A true MXPA02012067A (es) 2004-08-19

Family

ID=24349821

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012067A MXPA02012067A (es) 2000-06-05 2001-06-05 Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.

Country Status (7)

Country Link
US (6) US20040131585A1 (es)
EP (2) EP2324839B1 (es)
JP (3) JP5414958B2 (es)
AU (1) AU2001275339A1 (es)
CA (2) CA2412436C (es)
MX (1) MXPA02012067A (es)
WO (1) WO2001094420A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7291597B2 (en) * 2000-04-06 2007-11-06 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
AU2001275339A1 (en) 2000-06-05 2001-12-17 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002009650A2 (en) 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
KR20030034177A (ko) 2000-09-13 2003-05-01 쥬가이 세이야쿠 가부시키가이샤 허혈성 질환 치료제
SI1411918T1 (sl) 2001-07-31 2012-04-30 Genzyme Global S A R L Postopki za mobilizacijo progenitorskih/matičnih celic
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
PL210872B1 (pl) * 2001-12-21 2012-03-30 Immunex Corp Zastosowanie przeciwciała specyficznego dla P1H12 do wytwarzania wzbogaconej populacji komórek macierzystych oraz wzbogacona populacja komórek macierzystych i populacja komórek potomnych
AU2003224712A1 (en) * 2002-03-21 2003-10-08 University Of Florida Modulating angiogenesis
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2008121719A1 (en) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
AU2003296338A1 (en) * 2002-12-05 2004-06-30 Case Western Reserve University Cell-based therapies for ischemia
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP1611899A4 (en) * 2003-03-20 2009-07-01 Keiichi Fukuda COMBINED USE OF G-CSF AND ANGIOGENIC FACTOR
AR044315A1 (es) * 2003-05-16 2005-09-07 Kyowa Hakko Kogyo Kk Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido
DE10333901A1 (de) * 2003-07-21 2005-03-10 Transtissue Technologies Gmbh Verwendung von Chemokinen zur Rekrutierung von humanen mesenchymalen Vorläuferzellen zur Regeneration von Gelenkdefekten
EP1527785A1 (en) * 2003-10-27 2005-05-04 Ludwig-Maximilians-Universität München Use of G-CSF for treating ischemia
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
WO2005107817A2 (en) 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
WO2005113751A1 (en) 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
DE602005012962D1 (de) * 2004-08-13 2009-04-09 Medtronic Inc Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung
EP1827494A4 (en) * 2004-11-18 2010-02-17 Wayne Franco COMBINATION GROWTH THERAPY AND CELL THERAPY FOR THE TREATMENT OF ACUTE AND CHRONIC ORGANIC DISEASES
ES2485387T3 (es) * 2005-11-07 2014-08-13 Amorcyte, Inc. Composiciones y métodos de reparación de lesiones vasculares
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
CN101384706B (zh) 2006-02-16 2013-11-06 圣拉法埃莱医院有限公司 骨骼肌周成血管细胞和心脏中成血管细胞、其分离方法和用途
US8119123B2 (en) 2006-02-16 2012-02-21 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
EP2068897A1 (en) * 2006-10-03 2009-06-17 Medtronic, Inc. Endothelial progenitor cell compositions and neovascularization
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
JP2010520181A (ja) * 2007-03-02 2010-06-10 ナショナル・ユニバーシティ・オブ・アイルランド・ゴルウェイ 心血管疾患の予測および治療のためのオステオポンチン
US8496926B2 (en) * 2007-04-16 2013-07-30 Biocardia, Inc. Treatment for chronic myocardial infarction
MX2010001307A (es) * 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
LT2190991T (lt) * 2007-08-06 2020-02-10 Noxxon Pharma Ag Sdf-1 surišančios nukleorūgštys ir jų panaudojimas
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
GB0818725D0 (en) 2008-10-13 2008-11-19 Habib Nagy A Pharmaceutical composition
CN102245189B (zh) * 2008-12-03 2015-06-17 阿莫塞特公司 改善梗死区灌注的组合物以及血管损伤修复方法
AU2010286511B2 (en) 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
HUE053293T2 (hu) * 2009-12-11 2021-06-28 Medregen Llc Õssejt-mobilizátorokat és immunszuppresszív szereket alkalmazó kezelési módszerek
WO2011082339A2 (en) * 2009-12-31 2011-07-07 Cedars-Sinai Medical Center Regeneration of, reestablishing function in and replacing microvasculature in organs and tissues
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
AU2012268078B2 (en) 2011-06-07 2017-06-01 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
AR087363A1 (es) 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
US20130231647A1 (en) * 2012-03-05 2013-09-05 BFM Group International GMBH Laser therapy for endogenously enhancing ventricular function
EP2905331A4 (en) * 2012-10-05 2016-04-06 Samsung Life Public Welfare Foundation COMPOSITION WITH AN ISCHEMIC SERUM FOR PROMOTING STM CELL ACTIVATION AND METHOD FOR PROMOTING STEM CELL ACTIVATION
EP3139945A4 (en) 2014-05-08 2017-11-29 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
JP7352807B2 (ja) 2017-04-12 2023-09-29 マジェンタ セラピューティクス インコーポレイテッド アリール炭化水素受容体アンタゴニスト及びその使用
WO2019032930A1 (en) 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
AU2018358054A1 (en) 2017-10-31 2020-05-07 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
JP7412341B2 (ja) 2017-10-31 2024-01-12 エディジーン バイオテクノロジー インコーポレイテッド 造血幹細胞および前駆細胞の増幅のための組成物および方法
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2020005878A (es) 2017-12-06 2020-10-07 Magenta Therapeutics Inc Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas.
CN111902411A (zh) 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
KR102056447B1 (ko) * 2018-03-16 2019-12-16 (주)메디노 신경줄기세포를 이용한 혈관형성 유도 방법
EP4051298A1 (en) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
EP4143302A1 (en) 2020-04-27 2023-03-08 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107195A (en) * 1870-09-06 Improvement in sawing-machine
US5008284A (en) * 1989-02-15 1991-04-16 E. R. Squibb & Sons, Inc. Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
EP0483247A4 (en) * 1989-07-21 1992-12-09 Washington University Recombinantly produced human membrane cofactor protein (mcp)
EP0504257A4 (en) * 1989-11-29 1993-03-03 Brigham And Women's Hospital (ala il-8) 77 as a leukocyte adhesion inhibitor
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
JP2697495B2 (ja) * 1991-06-19 1998-01-14 富士レビオ株式会社 アルデヒド誘導体
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
JPH07166906A (ja) * 1993-12-14 1995-06-27 Nissan Motor Co Ltd 燃料カットと点火時期変更による加速スリップ制御装置
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US6110889A (en) * 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
JP3866800B2 (ja) * 1996-08-29 2007-01-10 東菱薬品工業株式会社 アポトーシス関連疾患の予防及び／又は治療薬
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
EP0897980A3 (en) * 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
US5880090A (en) * 1997-09-19 1999-03-09 The Hope Heart Institute Treatment of vascular graft implants with G-CSF
WO1999017798A1 (en) 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
CA2305234A1 (en) * 1997-10-06 1999-04-15 Acculase Inc. Methods and apparatus for ablating tissue
WO1999037779A1 (en) * 1998-01-22 1999-07-29 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
AU2469299A (en) * 1998-01-23 1999-08-09 Cornell Research Foundation Inc. Purified populations of stem cells
MXPA00008352A (es) * 1998-02-27 2002-10-17 Univ Pennsylvania Vacunas, composiciones inmunoterapeuticas y metodos para usar las mismas.
WO1999045775A1 (en) * 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
WO1999065507A1 (en) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulating platelet function
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
AU767402B2 (en) 1999-03-30 2003-11-06 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US20060057722A1 (en) * 1999-03-30 2006-03-16 Myocardial Therapeutics, Inc. Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
US20060051334A1 (en) * 1999-03-30 2006-03-09 Myocardial Therapeutics, Inc. Injection of bone marrow-derived conditioned medium for angiogenesis
CA2381780C (en) * 1999-08-13 2015-03-10 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
AU2001275339A1 (en) * 2000-06-05 2001-12-17 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1311547A2 (en) * 2000-08-22 2003-05-21 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of cardiovascular conditions
AU2001290694A1 (en) * 2000-09-08 2002-03-22 The Regents Of The University Of California Gene and sequence variation associated with lipid disorder
KR20030034177A (ko) * 2000-09-13 2003-05-01 쥬가이 세이야쿠 가부시키가이샤 허혈성 질환 치료제
WO2002036078A2 (en) 2000-11-05 2002-05-10 University Of Florida Targeting pluripotent stem cells to tissues
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
JP2006500923A (ja) 2002-08-01 2006-01-12 ノースウェスタン ユニバーシティ ＩｇＥタンパク質の変異体およびその使用
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US7575794B2 (en) * 2006-08-29 2009-08-18 Corning Incorporated High strength substantially non-microcracked cordierite honeycomb body and manufacturing method
US7959387B2 (en) 2007-10-03 2011-06-14 Kennametal Inc. Shrink fit sleeve for tool holder

Also Published As

Publication number Publication date
CA2412436A1 (en) 2001-12-13
WO2001094420A1 (en) 2001-12-13
EP1290033A4 (en) 2004-12-08
AU2001275339A1 (en) 2001-12-17
US20100209401A1 (en) 2010-08-19
EP2324839A1 (en) 2011-05-25
US20090142296A1 (en) 2009-06-04
US9387234B2 (en) 2016-07-12
EP1290033B1 (en) 2012-10-31
JP2014001221A (ja) 2014-01-09
EP1290033A1 (en) 2003-03-12
WO2001094420B1 (en) 2002-03-07
US20080057069A1 (en) 2008-03-06
EP2324839B1 (en) 2017-08-09
US8486416B2 (en) 2013-07-16
JP5710709B2 (ja) 2015-04-30
JP2004509847A (ja) 2004-04-02
US20040131585A1 (en) 2004-07-08
JP5710574B2 (ja) 2015-04-30
US20060111290A1 (en) 2006-05-25
CA2810249A1 (en) 2001-12-13
CA2412436C (en) 2013-05-21
US7662392B2 (en) 2010-02-16
JP2013063979A (ja) 2013-04-11
JP5414958B2 (ja) 2014-02-12
US8153113B2 (en) 2012-04-10
US20150150943A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
MXPA02012067A (es) Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
WO2002008389A3 (en) Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
HK1126519A1 (en) Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
CA2747794A1 (en) Treatment of lung and pulmonary diseases and disorders
HK1068913A1 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
ES2572211T3 (es) Regeneración de músculo esquelético utilizando células madre mesenquimales
HUP0203781A2 (hu) Májszövet-forrás
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
DE60140200D1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
WO2002088328A8 (en) Method for generating highly active human dendritic cells from monocytes
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
HK1068256A1 (en) Compositions comprising organic extracts of geum japonicum thunb var. and the use thereof
WO2003000009A3 (en) Stimulation of vascularization with vegf-b
RU2018111216A (ru) Образование кости
ATE471155T1 (de) Neues impfstoffadjuvans und dessen herstellung und verwendung
ES2170726A1 (es) Procedimiento para la obtencion de un extracto aislado de la planta cyclamen europaeum l. y su utilizacion como agente terapeutico.
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
Wace et al. Laconia: II. Geraki
FR2809725B1 (fr) Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
DE60042776D1 (de) Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen
NO20010488D0 (no) Fremgangsmåte ved ex vivo behandling av allogene og xenogene T-celler med gp39-antagonister

Legal Events

Date Code Title Description
FG Grant or registration